You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四环医药(00460.HK)与STRIDESLIMITED成立合资公司在中国供应及分销四个药品
格隆汇 07-29 18:37

格隆汇7月29日丨四环医药(00460.HK)宣布,公司全资子公司耀忠国际已与Strides Limited全资子公司Strides新加坡子公司成立合资公司。合资公司将主要从事药品的注册申报及销售业务,分别由耀忠国际及Strides新加坡子公司各占51%及49%股权。

根据相关协议,合资公司将获得独家授权在中国注册申报、商业化及分销Strides Limited的四个产品("该等产品")。耀忠国际将负责该等产品在中国的注册申报、商业化及分销,而Strides Limited将会生产及供应该等产品的制成品。

Strides Limited将会向合资公司授权该等产品,并可选择随后扩大产品组合。Strides Limited将通过其在印度和新加坡的制造工厂向合资公司供应该等产品。

此次合作将为集团现有产品组合增添四个产品,将进一步丰富集团的产品线及有助集团拓展更多治疗领域市场。集团与Strides Limited的合作为两家公司建立紧密的合作关系,预期通过未来的战略合作将可进一步扩展和开发更多有潜力的产品合作。

Strides Limited是一家成立于1990年,在孟买交易所(股份代号:532531)及印度国家证券交易所(股份代号:STAR)上巿,总部位于印度班加罗尔的全球制药公司。Strides Limited在全球三大洲拥有七个生产基地,其中五个获得了美国食品药品监督管理局(FDA)认证,另外两个则面向新兴市场。Strides Limited在印度拥有专门的研发机构,具备全球申报注册的能力,并且在超过100个国家或地区拥有强大的业务覆盖能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account